Tramadol News and Research

RSS
Diabetic Neuropathy: Drug having disease-modifying potential will earn 40% patient share in the U.S

Diabetic Neuropathy: Drug having disease-modifying potential will earn 40% patient share in the U.S

Labopharm's public offering underwriters exercise over-allotment option to purchase additional 1.7M units

Labopharm's public offering underwriters exercise over-allotment option to purchase additional 1.7M units

Labopharm closes previously announced underwritten public offering of 11,764,706 units

Labopharm closes previously announced underwritten public offering of 11,764,706 units

Cipher Pharmaceuticals announces fourth-quarter and fiscal year 2009 results

Cipher Pharmaceuticals announces fourth-quarter and fiscal year 2009 results

Labopharm prices underwritten public offering of 11.7M units

Labopharm prices underwritten public offering of 11.7M units

New pain management options for patients undergoing knee or hip replacements

New pain management options for patients undergoing knee or hip replacements

Labopharm begins proposed public offering of common stock

Labopharm begins proposed public offering of common stock

FDA approves Amneal Pharmaceuticals' Tramadol/APAP tablets

FDA approves Amneal Pharmaceuticals' Tramadol/APAP tablets

FDA approves Labopharm's OLEPTRO antidepressant for MDD

FDA approves Labopharm's OLEPTRO antidepressant for MDD

Labopharm settles $1 million standby equity distribution with YA Global Master SPV

Labopharm settles $1 million standby equity distribution with YA Global Master SPV

Further stay of Cipher's NDA for CIP-TRAMADOL ER terminated

Further stay of Cipher's NDA for CIP-TRAMADOL ER terminated

FREEDRUGCARD.US launches new Rx savings program to reduce prescription drug prices

FREEDRUGCARD.US launches new Rx savings program to reduce prescription drug prices

Labopharm intends to draw down $1 million on SEDA; issues discount shares to YA Global Master

Labopharm intends to draw down $1 million on SEDA; issues discount shares to YA Global Master

MSD to distribute and market Labopharm's Tradorec XL in the U.K.

MSD to distribute and market Labopharm's Tradorec XL in the U.K.

Labopharm commences regulatory approval process in Europe for its twice-daily tramadol-acetaminophen

Labopharm commences regulatory approval process in Europe for its twice-daily tramadol-acetaminophen

Labopharm enters into standby equity distribution agreement with YA Global Master

Labopharm enters into standby equity distribution agreement with YA Global Master

FDA approves Par Pharmaceutical's new painkiller drug

FDA approves Par Pharmaceutical's new painkiller drug

Potential benefits of Labopharm's novel trazodone formulation published

Potential benefits of Labopharm's novel trazodone formulation published

Third-quarter financial results for the year 2009 announced by Biovail

Third-quarter financial results for the year 2009 announced by Biovail

Cipher Pharmaceuticals announces financial results for the third quarter of 2009

Cipher Pharmaceuticals announces financial results for the third quarter of 2009